As advancements in embryo editing technology continue to evolve, ethical considerations are once again coming to the forefront of public discourse.
The ongoing debates are fueled by the implications these technologies may have on healthcare and biotechnology, raising questions about their potential applications and consequences.
In light of these developments, stakeholders in the biotech industry are urged to engage in thoughtful discussions regarding the ethical frameworks that should guide these innovations.
Updates
Update at 13:40 UTC on 2026-06-26
STAT reported Cassidy targets 340B, Eli Lilly's mysterious retatrutide patient, and more biotech news from The Readout.
Sources: STAT